{"disease":{"id":"active-systemic-lupus-erythematosus","name":"active systemic lupus erythematosus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT06485674","title":"Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus","phase":"","overall_status":"COMPLETED","enrollment_count":561,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02794285","title":"Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":559,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02446912","title":"Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02446899","title":"Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":373,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04931563","title":"Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04680637","title":"Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":168,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04751396","title":"Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors","phase":"","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07311200","title":"A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"InventisBio Co., Ltd","has_results":false},{"nct_id":"NCT06694298","title":"A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}